Amir Fathi1, Mark Levis. 1. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA.
Abstract
PURPOSE OF REVIEW: Ever since the recognition that FMS-like tyrosine kinase 3 (FLT3) mutations exert a profound negative prognostic impact on the clinical outcome of patients with acute myeloid leukemia (AML), researchers have sought to find effective small-molecule inhibitors of this receptor tyrosine kinase. This review will attempt to provide a survey of the FLT3 inhibitors currently under investigation and provide a discussion on their current status in clinical trials. RECENT FINDINGS: Over the past 10 years, a number of different compounds have been studied in vitro and clinically as FLT3 inhibitors. The first inhibitors studied were hampered by cumbersome pharmacokinetics and a general lack of potency. However, some agents have shown promise in clinical trials with transient responses in AML. Newer compounds, such as AC220, have demonstrated profound selectivity and potency against the FLT3 target, and are currently being investigated in clinical trials. SUMMARY: Clinical trials have so far demonstrated that inhibitors of FLT3 do have clinical activity in patients with FLT3-mutant AML, although this activity is often transient and correlates with effective in-vivo suppression of the FLT3 target. As newer, more potent agents are now entering advanced clinical trials, opportunities will emerge for real progress against this grim disease.
PURPOSE OF REVIEW: Ever since the recognition that FMS-like tyrosine kinase 3 (FLT3) mutations exert a profound negative prognostic impact on the clinical outcome of patients with acute myeloid leukemia (AML), researchers have sought to find effective small-molecule inhibitors of this receptor tyrosine kinase. This review will attempt to provide a survey of the FLT3 inhibitors currently under investigation and provide a discussion on their current status in clinical trials. RECENT FINDINGS: Over the past 10 years, a number of different compounds have been studied in vitro and clinically as FLT3 inhibitors. The first inhibitors studied were hampered by cumbersome pharmacokinetics and a general lack of potency. However, some agents have shown promise in clinical trials with transient responses in AML. Newer compounds, such as AC220, have demonstrated profound selectivity and potency against the FLT3 target, and are currently being investigated in clinical trials. SUMMARY: Clinical trials have so far demonstrated that inhibitors of FLT3 do have clinical activity in patients with FLT3-mutant AML, although this activity is often transient and correlates with effective in-vivo suppression of the FLT3 target. As newer, more potent agents are now entering advanced clinical trials, opportunities will emerge for real progress against this grim disease.
Authors: George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali Journal: Lancet Date: 2006-10-14 Impact factor: 79.321
Authors: D Auclair; D Miller; V Yatsula; W Pickett; C Carter; Y Chang; X Zhang; D Wilkie; A Burd; H Shi; S Rocks; R Gedrich; L Abriola; H Vasavada; M Lynch; J Dumas; P A Trail; S M Wilhelm Journal: Leukemia Date: 2007-01-04 Impact factor: 11.528
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Steven Knapper; Alan K Burnett; Tim Littlewood; W Jonathan Kell; Sam Agrawal; Raj Chopra; Richard Clark; Mark J Levis; Donald Small Journal: Blood Date: 2006-07-20 Impact factor: 22.113
Authors: Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard Stone; Daniel Deangelo; Ilene Galinsky; Frank Giles; Elihu Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small Journal: Blood Date: 2006-07-20 Impact factor: 22.113
Authors: Daniel J DeAngelo; Richard M Stone; Mark L Heaney; Stephen D Nimer; Ronald L Paquette; Rebecca B Klisovic; Michael A Caligiuri; Michael R Cooper; Jean-Michel Lecerf; Michael D Karol; Shihong Sheng; Nick Holford; Peter T Curtin; Brian J Druker; Michael C Heinrich Journal: Blood Date: 2006-08-10 Impact factor: 22.113
Authors: Steven Knapper; Kenneth I Mills; Amanda F Gilkes; Steve J Austin; Val Walsh; Alan K Burnett Journal: Blood Date: 2006-07-25 Impact factor: 22.113
Authors: Hanna S Radomska; Meritxell Alberich-Jordà; Britta Will; David Gonzalez; Ruud Delwel; Daniel G Tenen Journal: J Clin Invest Date: 2012-07-17 Impact factor: 14.808